Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, TPX, Peacefulwendy, $Pistol Pete$, thenewmixer, fraum
Search This Board: 
Last Post: 8/18/2017 10:37:09 PM - Followers: 791 - Board type: Free - Posts Today: 0

Welcome to PharmaCyte BioTech
An OTCQB Company

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.



FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment

European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary,
PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment

 Company Address
PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92652
Office Number: 917.595.2850
Facsimile Number: 917.595.2851

Market Value:
$122,386,272 a/o Dec 19, 2016

Shares Outstanding:
848,904,665 a/o Aug 29, 2016

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

817,204,665 a/o Aug 29, 2016

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Stonegate Capital Inc.
8201 Preston Road
Suite 325
Dallas, TX 75225
United States


   All News Releases:


What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director

Carlos A. Trujillo – Chief Financial Officer and Director

Walter H. Gunzburg – Chief Scientific Officer

Dr. Matthias Lohr as Chairman of Scientific Advisory Board

Thomas Liquard - Chairman of the Audit Committe

  Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development

Dr. Manuel Hidalgo, Scientific Advisory Board





-  The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
-  We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
-  There are no guarantees when buying or selling any security.



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB News: Annual Report (10-k) 07/27/2017 05:24:39 PM
PMCB News: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 07/26/2017 09:00:00 AM
PMCB News: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 07/10/2017 09:30:00 AM
PMCB News: Current Report Filing (8-k) 07/10/2017 06:04:49 AM
PMCB News: PharmaCyte Biotech Releases Presentation to Oncologists and Interviews from 2017 ASCO Meeting Event 07/06/2017 09:00:00 AM
#69766  Sticky Note $PMCB Institutional Investors PMCB $Pistol Pete$ 06/10/17 11:37:09 PM
#68353  Sticky Note PMCB NEWS! PharmaCyte Biotech Updates IND Submission Process TPX 05/08/17 09:12:03 AM
#62231  Sticky Note in full/ #2/ 01-28-2017/ Keeping an Eye on mick 01/28/17 07:35:33 PM
#52881  Sticky Note Here is a very nice list of accomplishments... Peacefulwendy 09/28/16 11:17:44 AM
#73962   $PMCB check out this link and see PMCB $Pistol Pete$ 08/18/17 10:37:09 PM
#73961   I guess you are saying PMCB' s treatment fishon101 08/18/17 10:28:54 PM
#73960   $PMCB $Pistol Pete$ 08/18/17 08:35:46 PM
#73959   Yes for sure it will happen $Pistol Pete$ 08/18/17 08:09:49 PM
#73956   PMCB purchased the rights to "CapCell" renamed "Cell JoeDaddy 08/18/17 05:24:21 PM
#73955   IND in the Fall followed by several stages oldmusky 08/18/17 04:42:46 PM
#73952   Ha, I like the positivity but those are XCypher73 08/18/17 04:35:15 PM
#73950   I got it my Friend $Pistol Pete$ 08/18/17 04:13:52 PM
#73949   Lock up your shares and get ready $$$$ TheBestInvest 08/18/17 04:13:20 PM
#73948   Nice close ;-) Go $PMCB $Pistol Pete$ 08/18/17 04:01:06 PM
#73947   $PMCB 15' Chart $Pistol Pete$ 08/18/17 02:54:59 PM
#73946   Yeah, the charts posted here always look good...(yawn)... PINKribbon 08/18/17 01:08:57 PM
#73945   $PMCB Enjoy Corporate Video PMCB [/b $Pistol Pete$ 08/18/17 12:59:20 PM
#73944   Yet no one is buying at .066. concordia 08/18/17 12:16:54 PM
#73943   we got funding for pc and diabetes. tulla236a 08/18/17 12:10:53 PM
#73941   exactly the same thing. concordia 08/18/17 12:05:16 PM
#73940   There are 226,600 shares on the ask at concordia 08/18/17 11:59:16 AM
#73939   Thats what Wikipedia says... TheBestInvest 08/18/17 11:59:15 AM
#73938   Under United States patent law, a provisional application concordia 08/18/17 11:55:25 AM
#73937   No but you can create a tire and TheBestInvest 08/18/17 11:53:48 AM
#73936   Hang tight my Friend. It will come $Pistol Pete$ 08/18/17 11:49:05 AM
#73935   chart does look good - that's for sure NEWgene55 08/18/17 11:47:06 AM
#73933   PharmaCyte’s platform technology?? What's that cell-in-a-box? Not theirs. Also frosr6 08/18/17 11:38:02 AM
#73932   Didnt you say SMMG is garbage? Lets focus TheBestInvest 08/18/17 11:34:54 AM
#73931   Pmcb confirmed phase 3 trial! November 5 2013 Nuvilex, frosr6 08/18/17 11:32:10 AM
#73930   PMCB is patenting the use of CIAB with TheBestInvest 08/18/17 11:29:05 AM
#73929   CIAB is Batavian Nordics. Pmcb trying to re-patent frosr6 08/18/17 11:22:21 AM
#73924   Its a provisional patent and takes up to TheBestInvest 08/18/17 11:07:49 AM
#73923   True "Provisional patent applications are a way to frosr6 08/18/17 11:07:44 AM
#73922   Was it granted? Anyone can file a patent frosr6 08/18/17 11:05:22 AM
#73921   CEO confirmed in the CC that JDRF and TheBestInvest 08/18/17 11:05:00 AM
#73916   Also nobody is selling. People are waiting patiently TheBestInvest 08/18/17 10:54:46 AM
#73915   Provisional patent applications are a way to establish TheBestInvest 08/18/17 10:54:02 AM
#73913   Bavarian Nordic (Licensor and Owner) and Pharmacyte Licensee) frosr6 08/18/17 10:51:55 AM
#73912 TheBestInvest 08/18/17 10:47:15 AM
#73910   Can't re-patent same "shit" after it ran its frosr6 08/18/17 10:44:53 AM
#73908   Oh? Well they already lost it. The frosr6 08/18/17 10:39:06 AM
#73906   Should be. Pmcb has no legal agreement in frosr6 08/18/17 10:34:30 AM
#73905   No really. The news was released a few JODI1 08/18/17 10:20:39 AM
#73903   I guess .0659 is to much to pay concordia 08/18/17 10:13:49 AM
#73902   Scary. oldmusky 08/18/17 09:58:02 AM
#73901   $PMCB PharmaCyte Biotech - Diabetes Treatm $Pistol Pete$ 08/18/17 09:49:31 AM
#73900   My 1 allowed post: Trading; rcstock 08/18/17 09:47:11 AM
#73899   I'm still waiting for the bid news on frosr6 08/18/17 09:45:08 AM
#73898   Is .066 or .0675 too much to pay frosr6 08/18/17 09:39:28 AM
#73897   I still believe the IND submission will be JODI1 08/18/17 09:37:31 AM
#73896   It has "only" been 2639 days since this concordia 08/18/17 09:33:20 AM
#73895   The term of the Bavarian Nordic/GSF License Agreement frosr6 08/18/17 09:25:17 AM
#73894   BULLSHIT not just part of this post or frosr6 08/18/17 09:21:37 AM
#73893   IND is coming, just keep buying when you can. rudygerner 08/18/17 09:07:34 AM